Key Takeaways
- AbbVie commands an average brokerage score of 1.61 (positioned between Strong Buy and Buy) across 32 analyst firms, including 21 Strong Buy recommendations
- Citi and UBS each elevated their ABBV price objectives to $260 from previous $230 targets
- Both financial institutions continue holding Neutral ratings despite increased price expectations
- Zacks assigns ABBV a Rank #4 (Sell), noting the consensus EPS projection for this year declined 0.6% to $14.23
- GuruFocus identifies ABBV as approximately 16.4% above fair value, sporting a P/E ratio of 121.77x compared to its 5-year median of 47.36x
AbbVie (ABBV) has captured Wall Street’s focus this week as two prominent financial institutions elevated their price projections — yet neither is recommending investors add the stock to their portfolios.
ABBV shares were hovering near $247.19 according to recent market data, with both Citi and UBS establishing fresh $260 price objectives, representing an increase from their prior $230 marks. This reflects a 13% upward revision in anticipated value. However, both institutions maintained their Neutral positions, signaling they’re not enthusiastically endorsing the stock.
Citi’s analyst Geoff Meacham implemented this adjustment while preparing his Q2 earnings outlook for the biopharmaceutical sector. The institution anticipates “largely robust” second-quarter performance from the major pharmaceutical companies under its coverage. UBS analyst Michael Yee mirrored this tempered confidence — elevated target, unchanged neutral perspective.
The contradictory indicators continue beyond these assessments.
AbbVie’s average brokerage recommendation (ABR) spanning 32 institutions registers at 1.61 — formally positioned between Strong Buy and Buy classifications.
Among these 32 assessments, 21 rate it Strong Buy while two designate it as Buy. Superficially, this appears optimistic.
Yet Zacks presents a contrasting perspective.
Zacks Issues Sell Designation for ABBV
The current Zacks Rank for AbbVie stands at #4 (Sell). The Zacks Consensus Estimate for annual EPS has decreased 0.6% during the previous month, currently positioned at $14.23. Analysts have been progressively lowering their earnings projections, a pattern that Zacks considers significant.
Zacks emphasizes that brokerage assessments — despite widespread attention — frequently exhibit positive bias stemming from the business relationships firms maintain with covered companies. Their research demonstrates analysts distribute approximately five Strong Buy designations for each Strong Sell recommendation. Consequently, that 1.61 ABR might not represent the clear winner it initially appears.
The valuation analysis introduces additional complexity. GuruFocus establishes AbbVie’s GF Value at $212.31, positioning the present price approximately 16.4% beyond their calculation of fair value. The stock’s trailing P/E ratio stands at 121.77x — exceeding twice its five-year median of 47.36x.
GF Score and Corporate Insider Movements
GuruFocus assigns ABBV a GF Score of 81 from a possible 100, indicating strong comprehensive performance. Profitability receives an 8/10 rating while growth achieves 7/10. Financial strength, however, registers merely 4/10 — a metric deserving continued monitoring.
Regarding insider transactions, no purchases or sales have been documented over the preceding three months. Company insiders remain inactive.
AbbVie is scheduled to announce Q2 earnings shortly, and Citi’s forecast indicates the results could prove strong. The stock has gained roughly 1% during today’s session.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
